ニチグルカン関連論文

ニチグルカン関連の論文

AFO-202菌株由来
ニチグルカン　nichi Glucan®

N-163菌株由来
ニューリフィックス　neu REFIX®

ジャーナル掲載論文

2023-08:(N-163) Acta Myologica 2023. 2023 Dec 20

Raghavan K, Sivakumar T, Ichiyama K, Yamamoto N, Balamurugan M, Dedeepiya VD, Senthilkumar R, Preethy S, Abraham S
Efficacy of N-163 beta-glucan in beneficially improving biomarkers of relevance to muscle function in patients with muscular dystrophies in a pilot clinical study
パイロット臨床試験におけるN-163株β-グルカンによる筋ジストロフィー患者の筋機能に関連するバイオマーカーの改善効果
doi: 10.36185/2532-1900-312

2023-07:(N-163) Nature Scientific Reports 13, 17008 (2023)

Preethy S, Aoki Y, Minegishi K, Iwasaki M, Senthilkumar R, Abraham S
Resolution of fibrosis in mdx dystrophic mouse after oral consumption of N-163 strain of Aureobasidium pullulans produced β-glucan
アウレオバシジウム・プルランスN-163株β-グルカンの経口摂取によるmdxジストロフィーマウスの線維症の消失
doi: 10.1038/s41598-023-44330-0

2023-06:(N-163)　　J Smooth Muscle Res. 2023; 59: 67-80

Preethy S, Yamamoto N, Osaza S, Raghavan R, Dedeepiya V, Iwasaki M, Abraham S
Re-examining the therapeutic management of muscular dystrophies from a vascular smooth muscle-centred approach.
筋ジストロフィーの治療管理の再考―血管平滑筋を中心としたアプローチから
doi: 10.1540/jsmr.59.67.

2023-05:(N-163) IBRO Neuroscience reports 2023; 15: 90-99

Raghavan K, Dedeepiya VD, Srinivasan S, Pushkala S, Bharatidasan SS, Ikewaki N, Iwasaki M, Senthilkumar R, Preethy S, Abraham SJK
Beneficial immune-modulatory effects of the N-163 strain of Aureobasidium pullulans-produced 1,3-1,6 Beta glucans in Duchenne muscular dystrophy: Results of an open-label, prospective, exploratory case-control clinical study.
デュシェンヌ型筋ジストロフィーにおけるアウレオバシジウム・プルランスN-163株が産生する1,3-1,6β-グルカンの有益な免疫調節効果：非盲検前向き探索的症例対照臨床試験の結果
doi: 10.1016/j.ibneur.2023.06.007.

2023-04: (AFO-202, N-163) 　 Aging Res Lifestyle

Ikewaki N, Sonoda T, Kurosawa G, Iwasaki M, Dedeepiya VD, Senthilkumar R, Preethy S, Abraham S.
Beta 1,3-1,6 glucans produced by two novel strains of Aureobasidium pullulans exert immune and metabolic beneficial effects in healthy middle-aged Japanese men: Results of an exploratory randomized control study
日本人の健康な中年男性において、アウレオバシジウム・プルランスの2つの新規菌株が産生するβ1,3-1,6グルカンが免疫および代謝に有益な効果を発揮する：探索的ランダム化比較試験の結果
doi: 10.14283/jarlife.2023.11

2023-03: (AFO-202,N-163)　GEORGIAN MEDICAL NEWS No 3 (336) 2023

S Preethy , N Yamamoto , N Liem , S Bharatidasan , M Iwasaki , S Abraham.
Role of gut microbiome homeostasis, integrity of the intestinal epithelial cells, and the (endogenous) butyrate in enduring a healthy long life
健康長寿における腸内細菌叢の恒常性、腸管上皮細胞の完全性、（内因性）酪酸の役割
doi: 10.1159/000527728

2023-02: (AFO-202) 　JAMA Pediatr Published online April 03, 2023

Zeyan Liew, Qi Meng, Qi Yan, et al.
Gut microbiome evaluation in children with autism spectrum disorder after increased maternal lithium consumption, may throw further insight. Comment to: Liew Z, Meng Q, Yan Q, et al. Association Between Estimated Geocoded Residential Maternal Exposure to Lithium in Drinking Water and Risk for Autism Spectrum Disorder in Offspring in Denmark.
母親のリチウム摂取量増加後の自閉症スペクトラム障害児における腸内細菌叢の評価が、さらなる洞察をもたらす可能性：デンマークにおける、推定されたジオコード化された居住地における母親の飲料水中リチウム曝露と子供の自閉症スペクトラム障害リスクとの関連へのコメント
doi: 10.1001/jamapediatrics.2023.0346

2023-01: (AFO-202)　Vaccine 2023

Ikewaki N, Kurosawa G, Levy GA, Preethy S, Abraham S.
Antibody dependent disease enhancement (ADE) after COVID-19 vaccination and Beta Glucans as a safer strategy in management
COVID-19ワクチン接種後の抗体依存性疾患亢進（ADE）と、より安全な管理戦略としてのβグルカン
doi: 10.1016/j.vaccine.2023.03.005.

2022-10:（AFO-202）Med Princ Pract

Preethy S, Raghavan K, Ikewaki N, Abraham SJ.
Qualitative Evaluation of α-Synuclein – A Critical Step in Unraveling the Complexities of Autism Spectrum Disorder.
α-シヌクレインの定性的評価 – 複雑な自閉症スペクトラムの解明への重要なステップ
https://www.karger.com/Article/FullText/527728

2022-09:（AFO-202, N-163）BMJ Open Gastroenterology

Preethy S, Ikewaki N, Levy GA, Raghavan K, Dedeepiya VD, Yamamoto N, Srinivasan S, Ranganathan N, Iwasaki M, Senthilkumar R, Abraham SJK.
Two unique biological response-modifier glucans beneficially regulating gut microbiota and faecal metabolome in a non-alcoholic steatohepatitis animal model, with potential for applications in human health and disease.
非アルコール性脂肪肝動物モデルにおいて、腸内細菌叢と糞便中のメタボロームを調節する2種類のユニークな生体応答修飾グルカンが示すヒトの健康や疾患への応用の可能性
https://pubmed.ncbi.nlm.nih.gov/36167455/

2022-08:（AFO-202, N-163）Frontiers in Immunology

Preethy S, Raghavan K, Dedeepiya VD, Suryaprakash V, Ikewaki N, Ikeue Y, Nagataki M, Iwasaki M, Senthilkumar R, Abraham S.
Beneficial immune regulation by biological response modifier glucans in COVID-19 and their envisaged potentials in the management of sepsis.
COVID-19の生体応答修飾グルカンによる有益な免疫制御と敗血症の管理における可能性
https://www.frontiersin.org/articles/10.3389/fimmu.2022.870632/full

2022-07:（AFO-202）Journal of Alzheimer’s Disease

Preethy S, Ranganathan N, Raghavan K, Dedeepiya VD, Ikewaki N, Abraham S.
Integrating the Synergy of the Gut Microbiome into Regenerative Medicine: Relevance to Neurological Disorders
腸内細菌群の相乗効果の再生医療への統合；神経疾患との関連性
https://doi.org/10.3233/JAD-220313

2022-06:（AFO-202）Journal of Food Biochemistry

Ikewaki, N., Kurosawa, G., Kisaka, T. and Abraham, S.J.K. (2022),
Controlled modulation of all the arms of the immunity including innate immunity by biological response modifier glucans, a simple yet potential nutritional supplement strategy to fight COVID-19.
生体応答修飾物質グルカンによる自然免疫を含む免疫全般の制御、COVID-19と戦うためのシンプルで可能性のある栄養補助食品戦略
https://doi.org/10.1111/jfbc.14156

2022-05:（AFO-202）Journal of Alzheimer’s disease

Raghavan K, Dedeepiya VD, Yamamoto N, Ikewaki N, Sonoda T, Kurosawa G, Iwasaki M,Kandaswamy R, Senthilkumar R, Preethy S, Abraham SJK.
Benefits of Gut Microbiota Reconstitution by Beta 1,3-1,6 Glucans in Subjects with Autism Spectrum Disorder and Other Neurodegenerative Diseases
自閉症スペクトラム障害およびその他の神経変性疾患患者におけるβ1,3-1,6グルカンによる腸内細菌叢再構築の有用性
https://pubmed.ncbi.nlm.nih.gov/36093695/

2022-04: (AFO-202, N-163)　 Journal of Diabetes and Metabolic Disorders

Ikewaki N, Onaka T, Ikeue Y, Nagataki M, Kurosawa G, Dedeepiya VD, Rajmohan M, Vaddi S, Senthilkumar R, Preethy S, Abraham SJK.
Beneficial effects of 1,3–1,6 β-glucans produced by Aureobasidium pullulans on non-esterified fatty acid levels in diabetic KKAy mice and their potential implications in metabolic dysregulation
黒酵母が生産する 1,3-1,6 βグルカンの糖尿病性 KKAy マウスの非エステル化脂肪酸レベルに対する有益な効果と代謝異常への潜在的な影響について
https://doi.org/10.1007/s40200-022-01170-5

2022-03: (AFO-202, N-163)　 Brain and Behavior

Raghavan K, Dedeepiya VD, Kandaswamy R, Balamurugan M, Ikewaki N, Sonoda T, Kurosawa K, Iwasaki M, Preethy S, Abraham SJK.
Improvement of sleep and melatonin in children with autism spectrum disorder after β-1,3/1,6-glucan consumption: An open-label prospective pilot clinical study
β-1,3/1,6-グルカンの摂取による自閉症スペクトラム障害児の睡眠とメラトニンの改善：非盲検プロスペクティブパイロット臨床試験
https://doi.org/10.1002/brb3.2750

2022-02: (AFO-202, N-163）Journal of Clinical and Experimental Hepatology

Nobunao Ikewaki, Gary A. Levy, Gene Kurosawa, Masaru Iwasaki, Vidyasagar D. Dedeepiya, Suryaprakash Vaddi
Rajappa Senthilkumar, Senthilkumar Preethy, Samuel J.K. Abraham
Hepatoprotective Effects of Aureobasidium pullulans Derived β 1,3–1,6 Glucans in a Murine Model of Non-alcoholic Steatohepatitis
非アルコール性脂肪肝炎のSTAM動物モデルにおける黒酵母由来のβ1,3-1,6 biological response modifier glucansの肝保護作用に関する研究
https://www.sciencedirect.com/science/article/pii/S0973688322001608

2022-01: (AFO-202) 　BMJ Neurology Open

Raghavan K, Dedeepiya VD, Ikewaki N, Sonoda T, Iwasaki M, Preethy S, Abraham SJK.
Improvement of behavioural pattern and alpha-synuclein levels in autism spectrum disorder after consumption of a beta-glucan food supplement in a randomized, parallel-group pilot clinical study.
自閉症スペクトラム障害におけるβグルカン食品の摂取による行動パターンおよびαシヌクレインレベルの改善に関する無作為化並行群間パイロット臨床研究
http://dx.doi.org/10.1136/bmjno-2021-000203

2021-05: (AFO-202, N-163) Clinical Immunology Communications

Ikewaki N, Raghavan K, Dedeepiya VD, Suryaprakash V, Iwasaki M, Preethy S, senthilkumar R, Abraham SJK.
Beneficial immune-regulatory effects of novel strains of Aureobasidium pullulans AFO-202 and N-163 produced beta glucans in Sprague Dawley rats
黒酵母菌株AFO-202およびN-163が産生するβグルカンのSprague Dawleyラットにおける有益な免疫制御作用
https://www.sciencedirect.com/science/article/pii/S2772613421000081?via%3Dihub

2021-04: (AFO-202)　 Oncology Reports

Ikewaki N, Dedeepiya VD, Raghavan K, Rao K, Vaddi S, Osawa H, Kisaka T, Kurosawa G, Srinivasan S, Ganesakumar SRB, Senthilkumar R, Iwasaki M, Preethy S, Abraham SJK.
β‑glucan vaccine adjuvant approach for cancer treatment through immune enhancement (B‑VACCIEN) in specific immunocompromised populations (Review)
特定の免疫不全集団におけるβグルカンのワクチンアジュバント・アプローチによる免疫強化を通じた癌治療（B-VACCIEN）（レビュー）
https://www.spandidos-publications.com/10.3892/or.2021.8225

2021-03: (AFO-202, N-163) 　Biomedicine & Pharmacotherapy

Raghavan K, Dedeepiya VD, Suryaprakash V, Rao KS, Ikewaki N, Sonoda T, Levy GA, Iwasaki M, Senthilkumar R, Preethy S, Abraham SJK.
Beneficial Effects of novel Aureobasidium Pullulans strains produced Beta-1,3-1,6 Glucans on Interleukin-6 and D-Dimer levels in COVID-19 patients; results of a randomized multiple-arm pilot clinical study
COVID-19（新型コロナウィルス感染症）患者のIL-6およびD-ダイマー値に対する新規黒酵母菌株産生のβ-1,3-1,6グルカンの有益性；無作為化多群試験の結果
https://www.medrxiv.org/content/10.1101/2021.08.09.21261738v1

2021-02: (AFO-202) 　Human Vaccines & Immunotherapeutics

Ikewaki N, Iwasaki M, Kurosawa G, Rao KS, Beitia JL, Preethy S, Abraham SJK.
β-Glucans: Wide-spectrum Immune-balancing Food-supplement-based Enteric (β-WIFE) Vaccine Adjuvant Approach to COVID-19
特定の免疫不全集団におけるβグルカンのワクチンアジュバント・アプローチによる免疫強化を通じた癌治療（B-VACCIEN）（レビュー）
https://pubmed.ncbi.nlm.nih.gov/33651967/

2021-01: (AFO-202) Frontiers in Immunology

Ikewaki N, Dedeepiya VD, Iwasaki M, Abraham SJK.
Commentary: Beyond “TRIM” benefits of β-glucan by blood glucose and lipid balancing potentials in its defense Against COVID-19
COVID-19に対するβグルカンの防御による血糖値および脂質バランス調整能の「TRIM」効果を超えて
https://www.frontiersin.org/articles/10.3389/fimmu.2021.620658/full

2020-03: (AFO-202) Frontiers in Immunology

Rao K-S, Suryaprakash V, Senthilkumar R, Preethy S, Katoh S, Ikewaki N, Abraham SJK.
Role of Immune Dysregulation in Increased Mortality Among a Specific Subset of COVID-19 Patients and Immune-Enhancement Strategies for Combatting Through Nutritional Supplements
特定のCOVID-19（新型コロナウィルス感染症）患者の死亡率上昇における免疫調節の役割と、栄養補助食品による免疫強化の戦略
https://www.frontiersin.org/articles/10.3389/fimmu.2020.01548/full

2020-02: (AFO-202) Thrombosis Journal

Ikewaki N, Rao KS, Archibold AD, Iwasaki M, Senthilkumar R, Preethy S, Katoh S, Abraham SJK.
Coagulopathy associated with COVID-19 – Perspectives & Preventive strategies using a Biological Response Modifier Glucan.
COVID-19（新型コロナウィルス感染症）に伴う血液凝固異常-生物学的応答調節物質グルカンを用いた展望と予防策
https://thrombosisjournal.biomedcentral.com/articles/10.1186/s12959-020-00239-6

2020-01: (AFO-202)　　Journal of Diabetes & Metabolic Disorders volume

Ikewaki N, Iwasaki M, Abraham SJK.
Biological response modifier glucan through balancing of blood glucose may have a prophylactic potential in COVID-19 patients.
COVID-19（新型コロナウィルス感染症）患者における、血糖値のバランスを調整する生物学的応答調節物質グルカンによる予防の可能性
https://link.springer.com/article/10.1007/s40200-020-00664-4

2014-01: (AFO-202)　　Journal of Dietary Supplement

Ikewaki N, Iwasaki M, Abraham SJK.
Beneficial effects of Black yeast derived 1-3, 1-6 beta glucan- Nichi Glucan in a dyslipidemic individual of Indian origin A case report. J Diet Suppl.
インド人脂質異常症患者における黒酵母由来1-3, 1-6βグルカン-ニチグルカンの有用性ー症例報告
https://www.tandfonline.com/doi/full/10.3109/19390211.2013.859211

2012-01: (AFO-202)　　Case Reports in Medicine

Dedeepiya V, Sivaraman G,Venkatesh A, Preethy S, Abraham SJK.
Potential Effects of Nichi Glucan as a Food Supplement for Diabetes Mellitus and Hyperlipidemia; Preliminary Findings from the Study on Three Patients from India.
糖尿病および高脂血症に対するNichi Glucanの食品としての可能性
https://www.hindawi.com/journals/crim/2012/895370/

プリプリント掲載論文

５）　(N-163)

Raghavan K, Dedeepiya VD, Yamamoto N, Ikewaki N, Iwasaki M, Dinassing A, Senthilkumar R, Preethy S, Abraham SJK.
Randomised trial of Aureobasidium pullulans-produced beta 1,3-1,6-glucans in patients with Duchenne muscular dystrophy: Favourable changes in gut microbiota and clinical outcomes indicating their potential in epigenetic manipulation.
デュシェンヌ型筋ジストロフィー患者を対象としたAureobasidium pullulans産β1,3-1,6-glucansの無作為化試験：腸内細菌叢の好ましい変化とエピジェネティックな操作の可能性を示す臨床結果
https://www.medrxiv.org/content/10.1101/2022.12.09.22283273v1

４）　 (N-163)

Preethy S, Aoki Y, Minegishi K, Senthilkumar R, Abraham S.
Resolution of fibrosis in mdx dystrophic mouse after oral consumption of N-163 strain of Aureobasidium pullulans produced biological response modifier β-glucan (BRMG).
Aureobasidium pullulansのN-163株の生物学的応答修飾物質βグルカン（BRMG）経口摂取によるmdxジストロフィーマウスの線維化解消の検討
https://www.biorxiv.org/content/10.1101/2022.11.17.516628v1

３）　(AFO-202, N-163)

Pushkala S, Seshayyan S, Theranirajan E, Sudhakar D, Raghavan K, Dedeepiya VD, Ikewaki N,Iwasaki M, Preethy S, Abraham S.
Efficient control of IL-6, CRP and Ferritin in Covid-19 patients with two variants of Beta-1,3-1,6 glucans in combination, within 15 days in an open-label prospective clinical trial.
Covid-19患者における2種類のβ-1,3-1,6グルカンを併用した15日以内の非盲検前向き臨床試験におけるIL-6、CRP、フェリチンの効率的なコントロール
https://www.medrxiv.org/content/10.1101/2021.12.14.21267778v1

２)　（N-163）

Raghavan K, Dedeepiya VD, Srinivasan S, Pushkala S, Subramanian S, Ikewaki N, Iwasaki M, Senthilkumar R, Preethy S, Abraham S.
Disease-modifying immune-modulatory effects of the N-163 strain of Aureobasidium pullulans-produced 1,3-1,6 Beta glucans in young boys with Duchenne muscular dystrophy: Results of an open-label, prospective, randomized, comparative clinical study
Duchenne型筋ジストロフィーの少年におけるAureobasidium pullulans産の1,3-1,6βグルカンN-163株の疾患修飾免疫調節効果。非盲検前向き無作為化比較臨床試験結果
https://www.medrxiv.org/content/10.1101/2021.12.13.21267706v1

１）（AFO-202, N-163）

Ikewaki N, Sonoda T, Kurosawa G, Iwasaki M, Dedeepiya VD, Senthilkumar R, Preethy S, Abraham SJK.
Immune and metabolic beneficial effects of Beta 1,3-1,6 glucans produced by two novel strains of Aureobasidium pullulans in healthy middle-aged Japanese men: An exploratory study
健康な日本人中年男性における黒酵母の2つの新規菌株が産生するβ1,3-1,6グルカンの免疫および代謝への有益性探索的研究
https://www.medrxiv.org/content/10.1101/2021.08.05.21261640v1